MARKET

NXTC

NXTC

Nextcure
NASDAQ
11.28
+0.60
+5.62%
Opening 10:05 04/01 EDT
OPEN
10.96
PREV CLOSE
10.68
HIGH
11.28
LOW
10.96
VOLUME
1.47K
TURNOVER
--
52 WEEK HIGH
15.74
52 WEEK LOW
2.688
MARKET CAP
40.16M
P/E (TTM)
-0.5742
1D
5D
1M
3M
1Y
5Y
1D
NextCure, Simcere CDH6 ADC abstract accepted for ASCO meeting
Reuters · 21h ago
Weekly Report: what happened at NXTC last week (0323-0327)?
Weekly Report · 2d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 03/23 21:05
Weekly Report: what happened at NXTC last week (0316-0320)?
Weekly Report · 03/23 10:21
Weekly Report: what happened at NXTC last week (0309-0313)?
Weekly Report · 03/16 10:20
Weekly Report: what happened at NXTC last week (0302-0306)?
Weekly Report · 03/09 10:20
NextCure GAAP EPS of -$19.65
Seeking Alpha · 03/06 07:47
NextCure Publishes Corporate Presentation on Targeted ADC Cancer Therapies
Reuters · 03/05 21:18
More
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Webull offers NextCure Inc stock information, including NASDAQ: NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.